Comparative Pharmacology
Head-to-head clinical analysis: SULFONAMIDES DUPLEX versus SULPHRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFONAMIDES DUPLEX versus SULPHRIN.
SULFONAMIDES DUPLEX vs SULPHRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonamides are competitive antagonists of para-aminobenzoic acid (PABA) and inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Its active sulfide metabolite is responsible for therapeutic effects.
Oral: 500-1000 mg twice daily; maximum 2000 mg/day.
1-2 tablets (500-1000 mg paracetamol, 65-130 mg caffeine) orally every 4-6 hours as needed, not exceeding 8 tablets (4000 mg paracetamol) per day for adults.
None Documented
None Documented
Terminal half-life: 7-12 hours in patients with normal renal function; prolonged to 24-50 hours in renal impairment (CrCl <30 mL/min) due to reduced elimination.
2-3 hours; clinically, hepatic impairment may prolong to 5-10 hours requiring dose adjustment
Renal: 70-100% unchanged drug via glomerular filtration and tubular secretion; fecal/biliary: <5%.
Renal: 85-90% as glucuronide and sulfate conjugates, 5-10% unchanged; biliary/fecal: <5%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic